Meda Ab (MDABY) 15.5600 $MDABY
MEDA: Year-end Report, January-December 2014
Business Wire - Wed Feb 11, 1:21AM CST
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Thu Feb 05, 5:45AM CST
Presentation of Meda's Year-End Results 2014
BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda
PR Newswire - Tue Jan 27, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the U.S. Food and Drug Administration (FDA) and originally commercially launched in the United States in 2009.
BDSI: 14.92 (+0.93)
Meda reports change in number of shares and votes
M2 - Tue Dec 30, 6:20AM CST
Meda AB (STO:MEDA-A.ST) (Pink Sheets:MDABY), a specialty pharmaceutical company, on Tuesday announced an increase of shares and votes during December 2014 of a total of 33,224,306 shares of series A and the equivalent number of votes.
Change in Number of Shares and Votes in Meda
Business Wire - Tue Dec 30, 1:14AM CST
Regulatory News:
Meda and Cipla announce suing of Apotex to enforce Dymista patents
M2 - Thu Dec 04, 5:20AM CST
Meda AB (STO:MEDAA.ST), a specialty pharmaceutical company, and pharmaceutical company Cipla Ltd announced on Wednesday that they have sued Apotex Inc and Apotex Corp in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray.
Meda AB (publ) Extraordinary General Meeting Bulletin
Business Wire - Thu Nov 06, 7:56AM CST
Regulatory News:
Meda announces change in number of shares and votes
M2 - Fri Oct 31, 5:09AM CDT
Speciality pharmaceutical company Meda AB (STO:MEDAA.ST) announced today that as a part of the agreed purchase price for Rottapharm S.p.A., it has completed an issue of 30,000,000 series A shares in favour of Rottapharm's previous owners, Fidim S.r.l.
Meda announces appointment of nomination committee members for AGM 2015
M2 - Wed Oct 15, 6:49AM CDT
Specialty pharmaceutical company Meda AB (STO:MEDAA.ST) announced on Wednesday that the members of its nomination committee for the Annual General Meeting 2015 are Bert Ake Eriksson, committee chairman; Stena Sessan of Rederi AB; Sigieri Diaz Pallavicini of Fidim S.r.l; Evert Carlsson of Swedbank Robur Funds; Lars Backsell of B&E Participation/Flerie Invest; and Martin Svalstedt, Meda's chairman of the board of directors.
Notice of Extraordinary General Meeting in Meda Aktiebolag (publ)
Business Wire - Fri Oct 10, 10:19AM CDT
Regulatory News:
Organizational Change, Meda Inc. (US)
Business Wire - Thu Oct 02, 8:10AM CDT
Regulatory News:
Meda divests manufacturing unit in Lakewood, New Jersey
M2 - Fri Sep 05, 3:11AM CDT
Meda AB (STO: MEDAA), a specialty pharmaceutical company, announced on Thursday the signing of an agreement to divest the manufacturing unit in Lakewood, New Jersey, to the contract manufacturer DPT.
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
MEDA: Year-end Report, January-December 2014
Business Wire - Wed Feb 11, 1:21AM CST
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Thu Feb 05, 5:45AM CST
Presentation of Meda's Year-End Results 2014
BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda
PR Newswire - Tue Jan 27, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the U.S. Food and Drug Administration (FDA) and originally commercially launched in the United States in 2009.
BDSI: 14.92 (+0.93)
Meda reports change in number of shares and votes
M2 - Tue Dec 30, 6:20AM CST
Meda AB (STO:MEDA-A.ST) (Pink Sheets:MDABY), a specialty pharmaceutical company, on Tuesday announced an increase of shares and votes during December 2014 of a total of 33,224,306 shares of series A and the equivalent number of votes.
Change in Number of Shares and Votes in Meda
Business Wire - Tue Dec 30, 1:14AM CST
Regulatory News:
Meda and Cipla announce suing of Apotex to enforce Dymista patents
M2 - Thu Dec 04, 5:20AM CST
Meda AB (STO:MEDAA.ST), a specialty pharmaceutical company, and pharmaceutical company Cipla Ltd announced on Wednesday that they have sued Apotex Inc and Apotex Corp in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray.
Meda AB (publ) Extraordinary General Meeting Bulletin
Business Wire - Thu Nov 06, 7:56AM CST
Regulatory News:
Meda announces change in number of shares and votes
M2 - Fri Oct 31, 5:09AM CDT
Speciality pharmaceutical company Meda AB (STO:MEDAA.ST) announced today that as a part of the agreed purchase price for Rottapharm S.p.A., it has completed an issue of 30,000,000 series A shares in favour of Rottapharm's previous owners, Fidim S.r.l.
Meda announces appointment of nomination committee members for AGM 2015
M2 - Wed Oct 15, 6:49AM CDT
Specialty pharmaceutical company Meda AB (STO:MEDAA.ST) announced on Wednesday that the members of its nomination committee for the Annual General Meeting 2015 are Bert Ake Eriksson, committee chairman; Stena Sessan of Rederi AB; Sigieri Diaz Pallavicini of Fidim S.r.l; Evert Carlsson of Swedbank Robur Funds; Lars Backsell of B&E Participation/Flerie Invest; and Martin Svalstedt, Meda's chairman of the board of directors.
Notice of Extraordinary General Meeting in Meda Aktiebolag (publ)
Business Wire - Fri Oct 10, 10:19AM CDT
Regulatory News:
Organizational Change, Meda Inc. (US)
Business Wire - Thu Oct 02, 8:10AM CDT
Regulatory News:
Meda divests manufacturing unit in Lakewood, New Jersey
M2 - Fri Sep 05, 3:11AM CDT
Meda AB (STO: MEDAA), a specialty pharmaceutical company, announced on Thursday the signing of an agreement to divest the manufacturing unit in Lakewood, New Jersey, to the contract manufacturer DPT.
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
